MedWatch

Win-win or naivete? – Snipr Biome to spill its secrets

CEO Christian Grøndahl has decided to share Snipr’s patented knowledge of CRISPR with the world, hoping to one day reap the benefits it sows.

”It is partly out of altruism ... but it is also to make more people interested in doing research or partnership deals with us for the CRISPR medicines of the future," says Grøndahl | Photo: Snipr Biome/PR

Snipr Biome has built up something of a patent portfolio, now counting over 20 of the valuable protection slips, according to the company’s chief executive, Christian Grøndahl.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs